DDInter393 DDInter1658
Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Clarithromycin {u} (Compound) resembles {v} (Compound) Troleandomycin
Clarithromycin {u} (Compound) resembles {v} (Compound) Josamycin
Clarithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Azithromycin
Clarithromycin {u} (Compound) binds {v} (Gene) ABCB1
Clarithromycin {u} (Compound) upregulates {v} (Gene) SLC25A14
Clarithromycin {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Clarithromycin {u} (Compound) downregulates {v} (Gene) TIMM9
Clarithromycin {u} (Compound) causes {v} (Side Effect) Gingival bleeding
Clarithromycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amoxicillin
Clarithromycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cannabidiol
Clarithromycin (Compound) resembles Troleandomycin (Compound)
Clarithromycin (Compound) resembles Josamycin (Compound)
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin
Clarithromycin (Compound) binds ABCB1 (Gene)
Clarithromycin (Compound) upregulates SLC25A14 (Gene)
Clarithromycin (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class)
Clarithromycin (Compound) downregulates TIMM9 (Gene)
Clarithromycin (Compound) causes Gingival bleeding (Side Effect)
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Amoxicillin
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Cannabidiol